240 related articles for article (PubMed ID: 24118558)
1. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
DI Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
J Cardiovasc Electrophysiol; 2014 Feb; 25(2):197-207. PubMed ID: 24118558
[TBL] [Abstract][Full Text] [Related]
2. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
[TBL] [Abstract][Full Text] [Related]
3. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Di Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H104-17. PubMed ID: 23103500
[TBL] [Abstract][Full Text] [Related]
5. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
6. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
7. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the hERG safety margin after 20 years of routine hERG screening.
Leishman DJ; Abernathy MM; Wang EB
J Pharmacol Toxicol Methods; 2020 Sep; 105():106900. PubMed ID: 32768644
[TBL] [Abstract][Full Text] [Related]
9. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
Nogawa H; Kawai T
Eur J Pharmacol; 2014 Oct; 741():336-9. PubMed ID: 24998878
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
11. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
12. Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are I
Baburin I; Varkevisser R; Schramm A; Saxena P; Beyl S; Szkokan P; Linder T; Stary-Weinzinger A; van der Heyden MAG; Houtman M; Takanari H; Jonsson M; Beekman JHD; Hamburger M; Vos MA; Hering S
Pharmacol Res; 2018 May; 131():150-163. PubMed ID: 29477480
[TBL] [Abstract][Full Text] [Related]
13. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
[TBL] [Abstract][Full Text] [Related]
14. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
Witchel HJ; Hancox JC
Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
[TBL] [Abstract][Full Text] [Related]
15. Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and Mitigation.
Pearlstein RA; MacCannell KA; Erdemli G; Yeola S; Helmlinger G; Hu QY; Farid R; Egan W; Whitebread S; Springer C; Beck J; Wang HR; Maciejewski M; Urban L; Duca JS
Curr Top Med Chem; 2016; 16(16):1792-818. PubMed ID: 26975508
[TBL] [Abstract][Full Text] [Related]
16. The influence of hERG1a and hERG1b isoforms on drug safety screening in iPSC-CMs.
Goversen B; Jonsson MK; van den Heuvel NH; Rijken R; Vos MA; van Veen TA; de Boer TP
Prog Biophys Mol Biol; 2019 Dec; 149():86-98. PubMed ID: 30826123
[TBL] [Abstract][Full Text] [Related]
17. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
18. A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels.
Lin C; Cvetanovic I; Ke X; Ranade V; Somberg J
Am J Ther; 2005; 12(4):328-36. PubMed ID: 16041196
[TBL] [Abstract][Full Text] [Related]
19. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
Luo T; Luo A; Liu M; Liu X
Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
